EP1 receptor: Devil in emperors coat.
Alzheimer's disease
CNS
EP1 receptor
Parkinson's disease
neurodegeneration
Journal
Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
20
05
2023
received:
23
01
2023
accepted:
06
06
2023
medline:
23
8
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
ppublish
Résumé
EP1 receptor belongs to prostanoid receptors and is activated by prostaglandin E2. The receptor performs contrasting functions in central nervous system (CNS) and other tissues. Although the receptor is neurotoxic and proapoptotic in CNS, it has also been reported to act in an antiapoptotic manner by modulating cell survival, proliferation, invasion, and migration in different types of cancers. The receptor mediates its neurotoxic effects by increasing cytosolic Ca
Substances chimiques
Receptors, Prostaglandin E, EP1 Subtype
0
Protein Kinase C
EC 2.7.11.13
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1105-1114Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Jiang J, Qiu J, Li Q, Shi Z. Prostaglandin E2 signaling: alternative target for glioblastoma? Trends Cancer. 2017;3:75-78.
Li L, Sluter MN, Yu Y, Jiang J. Prostaglandin E receptors as targets for ischemic stroke: novel evidence and molecular mechanisms of efficacy. Pharmacol Res. 2021;163:105238.
Sun HJ, Wang SS, Li XY, Du JY, Fang JQ, Fang JF. [Advances of researches on peripheral PKCε pathway during transformation from acute to chronic pain and possibility of application of electroacupuncture intervention]. Zhen ci yan jiu = Acupuncture research. 2019;44:543-547.
Yagami T, Koma H, Yamamoto Y. Pathophysiological roles of cyclooxygenases and prostaglandins in the central nervous system. Mol Neurobiol. 2016;53:4754-4771.
Chell S, Kadi A, Caroline Williams A, Paraskeva C. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta Rev Cancer. 2006;1766(1):104-119.
Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res. 2006;66:9794-9797.
Ahmad AS, Saleem S, Ahmad M, Doré S. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci. 2006;89:265-270.
Kawano T, Anrather J, Zhou P, et al. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med. 2006;12:225-229.
Shenoda B. The role of Na+/Ca2+ exchanger subtypes in neuronal ischemic injury. Transl Stroke Res. 2015;6:181-190.
Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW. EP1 prostanoid receptor coupling to Gi/o up-regulates the expression of hypoxia-inducible factor-1α through activation of a phosphoinositide-3 kinase signaling pathway. Mol Pharmacol. 2010;77:1025-1036.
Chen C, Guan J, Gu X, Chu Q, Zhu H. Prostaglandin E2 and receptors: insight into tumorigenesis, tumor progression, and treatment of hepatocellular carcinoma. Front Cell Dev Biol. 2022;10:10.
Zhang H, Cheng S, Zhang M, et al. Prostaglandin E2 promotes hepatocellular carcinoma cell invasion through upregulation of YB-1 protein expression. Int J Oncol. 2014;44:769-780.
Mushtaq U, Shafi A, Khanday FA. Current challenges in Alzheimer's disease. Front Clin Drug Res Dementia. 2020;1:187.
2022 Alzheimer's disease facts and figures. Alzheimer's Dement. 2022;18:700-789.
Condello C, Merz GE, Aoyagi A, DeGrado WF, Prusiner SB. Aβ and tau prions causing Alzheimer's disease. Methods Mol Biol. 2023;2561:293-337.
Si ZZ, Zou CJ, Mei X, et al. Targeting neuroinflammation in Alzheimer's disease: from mechanisms to clinical applications. Neural Regen Res. 2023;18:708-715.
Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 1998;87:319-324.
Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609.
Sung S, Yang H, Uryu K, et al. Modulation of nuclear Factor-κB activity by indomethacin influences Aβ levels but not Aβ precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol. 2004;165:2197-2206.
Zhen G, Kim YT, Li R, et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease. Neurobiol Aging. 2012;33:2215-2219.
Mendes FR, Leclerc JL, Liu L, et al. Effect of experimental ischemic stroke and PGE2 EP1 selective antagonism in Alzheimer's disease mouse models. J Alzheimer's Dis. 2020;74:173-187.
Kurano M, Saito Y, Uranbileg B, et al. Modulations of bioactive lipids and their receptors in postmortem Alzheimer's disease brains. Front Aging Neurosci. 2022;14:1066578.
Adiga D, Radhakrishnan R, Chakrabarty S, Kumar P, Kabekkodu SP. The role of calcium signaling in regulation of epithelial-mesenchymal transition. Cells Tissues Organs. 2022;211:134-156.
Arjun McKinney A, Petrova R, Panagiotakos G. Calcium and activity-dependent signaling in the developing cerebral cortex. Development. 2022;149:14.
Cascella R, Cecchi C. Calcium dyshomeostasis in Alzheimer's disease pathogenesis. Int J Mol Sci. 2021;22:4914.
Datta D, Leslie SN, Wang M, et al. Age-related calcium dysregulation linked with tau pathology and impaired cognition in non-human primates. Alzheimer's Dementia. 2021;17:920-932.
Cao LL, Guan PP, Liang YY, Huang XS, Wang P. Cyclooxygenase-2 is essential for mediating the effects of calcium ions on stimulating phosphorylation of tau at the sites of Ser 396 and Ser 404. J Alzheimers Dis. 2019b;68:1095-1111.
Cao LL, Guan PP, Liang YY, Huang XS, Wang P. Calcium ions stimulate the hyperphosphorylation of tau by activating microsomal prostaglandin E synthase 1. Front Aging Neurosci. 2019a;11:108.
Perrot CY, Herrera JL, Fournier-Goss AE, Komatsu M. Prostaglandin E2 breaks down pericyte-endothelial cell interaction via EP1 and EP4-dependent downregulation of pericyte N-cadherin, connexin-43, and R-Ras. Sci Rep. 2020;10:11186.
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing Parkinson's disease: an environmental agenda. J Parkinson's Dis. 2022;12:45-68.
Weintraub D, Aarsland D, Chaudhuri KR, et al. The neuropsychiatry of parkinson's disease: advances and challenges. Lancet Neurol. 2022;21:89-102.
Seo BA, Kim D, Hwang H, et al. TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. Neuron. 2021;109:3758-3774.
Usmani A, Shavarebi F, Hiniker A. The cell biology of LRRK2 in Parkinson's disease. Mol Cell Biol. 2021;41:00660-20.
Guimarães RP, Ribeiro DL, Dos Santos KB, Godoy LD, Corrêa MR, Padovan-Neto FE. The 6-hydroxydopamine rat model of Parkinson's disease. J Vis Exp. 2021;27:62923.
Innos J, Hickey MA. Using rotenone to model Parkinson's disease in mice: a review of the role of pharmacokinetics. Chem Res Toxicol. 2021;34:1223-1239.
Mustapha M, Mat Taib CN. MPTP-induced mouse model of Parkinson's disease: a promising direction of therapeutic strategies. Bosn J Basic Med Sci. 2021;21:422-433.
Weed DL. Does paraquat cause Parkinson's disease? A review of reviews. Neurotoxicology. 2021;86:180-184.
Ahmad AS, Maruyama T, Narumiya S, Doré S. PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target. Neurotox Res. 2013;23:260-266.
Carrasco E, Casper D, Werner P. PGE2 receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE2 neurotoxicity. J Neurosci Res. 2007;85:3109-3117.
Hirai K, Hayashi T, Chan PH, et al. PI3K inhibition in neonatal rat brain slices during and after hypoxia reduces phospho-Akt and increases cytosolic cytochrome c and apoptosis. Mol Brain Res. 2004;124:51-61.
Luo HR, Hattori H, Hossain MA, et al. Akt as a mediator of cell death. Proc Natl Acad Sci. 2003;100:11712-11717.
Zhao H, Shimohata T, Wang JQ, et al. Akt contributes to neuroprotection by hypothermia against cerebral ischemia in rats. J Neurosci. 2005;25:9794-9806.
Zhou P, Qian L, Chou T, Iadecola C. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis. 2008;29:543-551.
Al-Nusaif M, Lin Y, Li T, Cheng C, Le W. Advances in NURR1-regulated neuroinflammation associated with Parkinson's disease. Int J Mol Sci. 2022;23:16184.
Ji R, Sanchez C, Chou C, Chen X, Woodward D, Regan J. Prostanoid EP1 receptors mediate up-regulation of the orphan nuclear receptor Nurr1 by cAMP-independent activation of protein kinase A, CREB and NF-κB: EP1 receptor up-regulation of Nurr1. Br J Pharmacol. 2012;166:1033-1046.
Ahmad AS, Kim YT, Ahmad M, Maruyama T, Doré S. Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. Neurotox Res. 2008;14:343-351.
Minami T, Nishihara I, Sakamoto K, Ito S, Hyodo M, Hayaishi O. Blockade by ONO-NT-012, a unique prostanoid analogue, of prostaglandin E2-induced allodynia in conscious mice. Br J Pharmacol. 1995;115:73-76.
Giblin GMP, Bit RA, Brown SH, et al. The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain. Bioorg Med Chem Lett. 2007;17:385-389.
Ostenfeld T, Beaumont C, Bullman J, Beaumont M, Jeffrey P. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A. Br J Clin Pharmacol. 2012;74:1033-1044.
Jin J, Chang Y, Wei W, et al. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin. 2012;33:701-709.
Falco-Walter J. Epilepsy-definition, classification, pathophysiology, and epidemiology. Semin Neurol. 2020;40:617-623.
Suleymanova EM. Behavioral comorbidities of epilepsy and neuroinflammation: evidence from experimental and clinical studies. Epilepsy & Behavior. 2021;117:107869.
Rojas A, Chen D, Ganesh T, Varvel NH, Dingledine R. The COX-2/prostanoid signaling cascades in seizure disorders. Expert Opin Ther Targets. 2019;23:1-13.
Reschke CR, Poersch AB, Masson CJ, et al. Systemic delivery of selective EP1 and EP3 receptor antagonists attenuates pentylenetetrazole-induced seizures in mice. Int J Physiol Pathophysiol Pharmacol. 2018;10:47-59.
Sun J, Zheng Y, Chen Z, Wang Y. The role of Na(+) -K(+) -ATPase in the epileptic brain. CNS Neurosci Ther. 2022;28:1294-1302.
Rojas A, Gueorguieva P, Lelutiu N, Quan Y, Shaw R, Dingledine R. The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticus. Neurobiol Dis. 2014;70:74-89.
Shafei I, Karnon J, Crotty M. Quality improvement in stroke rehabilitation: a scoping review. J Multidiscip Healthc. 2022;15:2913-2931.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke Statistics-2022 update: a report from the American heart association. Circulation. 2022;145:e153-e639.
Yang LX, Chen FY, Yu HL, et al. Poncirin suppresses lipopolysaccharide (LPS)-induced microglial inflammation and ameliorates brain ischemic injury in experimental stroke in mice. Ann Transl Med. 2020;8:1344.
Zhao X, Wu T, Chang CF, et al. Toxic role of prostaglandin E2 receptor EP1 after intracerebral hemorrhage in mice. Brain Behav Immun. 2015;46:293-310.
Yang HJ, Jiang JH, Yang YT, et al. Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor−1 expression predicts survival. World J Gastroenterol. 2016;22:8798-8805.
Bai X, Wang J, Zhang L, et al. Prostaglandin E2 receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells. Int J Oncol. 2013;42:1833-1841.
Mushtaq U, Bashir M, Nabi S, Khanday FA. Epidermal growth factor receptor and integrins meet redox signaling through P66shc and Rac1. Cytokine. 2021;146:155625.
Kawamori T, Uchiya N, Nakatsugi S, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001;22:2001-2004.
El-Ashmawy N, El-Zamarany E, Khedr E, Selim H, Khedr N. Blocking of the prostaglandin E2 receptor as a therapeutic strategy for treatment of breast cancer: promising findings in a mouse model. Asian Pacific J Cancer Prev. 2022;23:3763-3770.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
Zhu J, Mayr D, Kuhn C, Mahner S, Jeschke U, von Schönfeldt V. Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium. Histochem Cell Biol. 2018;149:153-160.
Rask K, Zhu Y, Wang W, Hedin L, Sundfeldt K. Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer. 2006;5:62.
Buchholz A, Vattai A, Fürst S, et al. Prostaglandin E2 receptor EP1 expression in vulvar cancer. J Cancer Res Clin Oncol. 2022;27:022-04487.
Dey I, Lejeune M, Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol. 2006;149:611-623.
Mushtaq U, Baba R, Parray AA, et al. Mitogen activated protein kinase kinase-4 upregulation is a frequent event in human stomach and colon cancers. Proteins. 2014;1:8.
Mizuno R, Kawada K, Sakai Y. Prostaglandin E2/EP signaling in the tumor microenvironment of colorectal cancer. Int J Mol Sci. 2019;20:6254.
Schumacher Y, Aparicio T, Ourabah S, et al. Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth. Oncogene. 2016;35:2602-2614.
Niu JC, Ma N, Liu W, Wang PJ. EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth. Bosn J Basic Med Sci. 2019;19:265-273.
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.
Miyata Y, Kanda S, Maruta S, et al. Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. Urology. 2006;68:1360-1365.
Masato M, Miyata Y, Kurata H, et al. Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model. Sci Rep. 2021;11:20279.
Yoshioka W, Tohyama C. Mechanisms of developmental toxicity of dioxins and related compounds. Int J Mol Sci. 2019;20:617.
Aida-Yasuoka K, Nishimura N, Fujisawa N, Endo N, Narumiya S, Tohyama C. The role of prostaglandin E(2) receptor EP1 in 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced neonatal hydronephrosis in mice. Toxicology. 2019;415:10-17.
Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nature Reviews Nephrology. 2020;16:269-288.
Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021;2021. doi:10.1155/2021/1497449
Li YY, Zhang XY. [Role of prostaglandin E2 in the modulation of renal water transport]. Sheng li xue bao: [Acta Physiol Sin]. 2021;73:681-689.
Swan CE, Breyer RM. Prostaglandin E2 modulation of blood pressure homeostasis: studies in rodent models. Prostagland Other Lipid Mediat. 2011;96:10-13.
Nasrallah R, Zimpelmann J, Robertson SJ, et al. Prostaglandin E2 receptor EP1 (PGE2/EP1) deletion promotes glomerular podocyte and endothelial cell injury in hypertensive TTRhRen mice. Lab Invest. 2020;100:414-425.
Thibodeau JF, Nasrallah R, Carter A, et al. PTGER1 deletion attenuates renal injury in diabetic mouse models. Am J Pathol. 2013;183:1789-1802.
Makino H, Tanaka I, Mukoyama M, et al. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. JASN. 2002;13:1757-1765.
Rutkai I, Feher A, Erdei N, et al. Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes. Cardiovasc Res. 2009;83:148-154.
Wu AM, Bisignano C, James SL, et al. Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Health Long. 2021;2:e580-e592.
Zhang M, Feigenson M, Sheu T, et al. Loss of the PGE2 receptor EP1 enhances bone acquisition, which protects against age and ovariectomy-induced impairments in bone strength. Bone. 2015;72:92-100.
Feigenson M, Jonason JH, Shen J, Loiselle AE, Awad HA, O'Keefe RJ. Inhibition of the prostaglandin EP-1 receptor in periosteum progenitor cells enhances osteoblast differentiation and fracture repair. Ann Biomed Eng. 2020;48:927-939.